Zymeworks stock
ZYMENASDAQZymeworks Inc., HealthcareISIN US98985Y1082
63Score 63 out of 100, Neutral
Price and trend
86 / 100
Price history
+37% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.8% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 43).
The price is 16% below its 52-week high. Largest decline in 10 years: 92% (January 2021 to September 2022).
Chart figures for advanced users
- SMA 50$27.39
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.50
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)43
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.50
- The lowest closing price of the last twelve months.
- Resistance$31.46
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Zymeworks Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.84B, is number 131 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $105.97M (up 38.9% year on year) and a loss of $81.13M.
- For fiscal 2026, analysts expect on average revenue of $322.34M (up 204.2%) and adjusted earnings per share of $1.26.
Show more
- MEQIRI Score 63 out of 100 (Neutral): rank 239 of 714 in Healthcare, median 53.
- The P/E is 46.7 (Biotechnology median 21.3, own median of recent years 4.1).
- Our model puts fair value at $19.66, with the price 48% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 16.3% over the last 12 months, Biotechnology median −93.3%.Profitability 86
Weaknesses
- DilutionShare count up 50% since 2020.Capital allocation 51
- Analysts expect falling earningsDown 24.6% a year through 2028 (estimates from 8 analysts).
- High debtDebt 2.57 times equity (latest quarter), Biotechnology median 0.09.Stability 45
Its standout strengths are momentum and profitability, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
One-off effect in revenue
In the quarter to 30 Sep 2026, revenue of $256.46M was about 9 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
What lowers it
- stable momentum
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $14.04 and expensive above $32.77 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $27.24 (cash-flow model) and $12.08 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 10.4%. At 11.4% the fair value would be $17.84, at 9.4% it would be $22.13.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 69.8% on the twelve months before. Revenue has grown strongly since 2014, at around 46% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −87%, net −77%. Last 12 months: net 16%.
Debt & balance sheet
latest quarterDebt is elevated; no interest coverage is reported.
Earnings
- Next earnings
- 1 Mar 2027in 109 days
- Last reported
- 9 Nov 2026EPS reported $2.28 (expected $2.27)in line with expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 27.2% since 15 Oct 2026.
- Earnings per share
- $1.26+20.3%
- Revenue
- $322.34M+8.7%
- Earnings per share
- $1.30+27.2%
- Revenue
- $350.77M+1.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −13.5%The IND for ZW1528 is now guided to 2027 instead of the prior expectation of 2026; the company says cash resources fund operations beyond 2028.
“I do want to highlight that we are now guiding to an IND in 2027 for ZW1528 compared to our prior expectation of 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $357,557 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Schayowitz AdamSale
9 Oct 2026, EVP, Head of R&D
- Shares
- 13,832
- Price
- $25.85
- Value
- $357,557
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Zymeworks
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 63
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Maravai LifeSciences HoldingsMRVI $2.19B38
- Lakefront BiotherapeuticsLKFT $2.18B73
- Aurinia PharmaceuticalsAUPH $2.17B69
- First Tracks BiotherapeuticsTRAX $2.12B47
- Harmony Biosciences HoldingsHRMY $2.01B73
- BioCryst PharmaceuticalsBCRX $1.97B37
- Agios PharmaceuticalsAGIO $1.96B40
- Zenas BioPharmaZBIO $1.95B38
ETFs that hold Zymeworks
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.13% | 0.35% | €1.21B |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.13% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.12% | 0.40% | €807M |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.09% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.07% | 0.43% | €2.48B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.